Silexion Therapeutics Corp
SLXN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SLXN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLXN
Silexion Therapeutics Corp (SLXN) is a development-stage biotechnology company focused on RNA interference (RNAi)-based therapies targeting KRAS-mutated cancers, with its lead candidate SIL204 in early clinical development and no approved products or revenue.
Key risk: Going concern risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Silexion Therapeutics Corp.
Silexion Therapeutics Corp (SLXN) is a development-stage biotechnology company focused on RNA interference (RNAi)-based therapies targeting KRAS-mutated cancers, with its lead candidate SIL204 in early clinical development and no approved products or revenue.
- Silexion is a development-stage company with no revenue from product sales and a history of significant operating losses, including a net loss of $11.9 million for the year ended December 31, 2025 [sec · filed 2026-08-07].
- As of June 30, 2026, the company reported cash and equivalents of $2.3 million and shareholders' equity of $2.6 million, with management expressing substantial doubt about its ability to continue as a going concern [sec · filed 2026-08-07].
- The lead product candidate, SIL204, is a locally administered siRNA targeting KRAS G12D and G12V mutations, currently in early-stage development with a planned Phase 2/3 clinical trial in locally advanced pancreatic cancer [sec_mda · as of 2026-08-14].
- The company has an accumulated deficit of $57.9 million as of March 31, 2026, and expects to continue incurring significant expenses for the foreseeable future [sec · filed 2026-08-07].
What works
- Silexion's RNAi platform targets KRAS mutations (G12D/G12V), a well-validated oncogenic driver, potentially addressing a large unmet need in pancreatic cancer and other solid tumors [sec · filed 2026-08-07].
- The company has initiated GMP batch manufacturing for SIL204 to support the planned human clinical trial, indicating progress toward clinical-stage development [sec · filed 2026-08-07].
- Silexion is actively building its intellectual property portfolio around its product candidates, which could provide competitive advantages if development succeeds [sec · filed 2026-08-07].
What to weigh
- Silexion has no approved products or revenue, and its lead candidate SIL204 is still in early preclinical/clinical stages, with no guarantee of successful development or commercialization [sec · filed 2026-08-07].
- The company has a very limited cash runway—$2.3 million as of June 30, 2026—and management has expressed substantial doubt about its ability to continue as a going concern without additional financing [sec · filed 2026-08-07].
- Silexion has a history of significant operating losses and an accumulated deficit of $57.9 million, with net losses expected to continue for the foreseeable future [sec · filed 2026-08-07].
- The company faces substantial capital requirements for clinical development, regulatory approvals, and potential commercialization, and may need to seek additional funds sooner than planned [sec · filed 2026-08-07].
From the filings
Quoted directly from source documents.
Silexion has no revenue from drug sales and may never commercialize a product.
“We currently generate no revenue from sales of any drugs or technology platforms, and we may never be able to develop or commercialize a marketable drug.”
SEC filings · August 7, 2026
Management has substantial doubt about the company's ability to continue as a going concern.
“Based upon our then-expected level of operating expenditures, we have substantial doubt about our ability to continue as a going concern as of such date.”
SEC filings · August 7, 2026
Silexion's lead candidate SIL204 targets KRAS G12D and G12V mutations.
“Our proposed treatment, which we refer to as SIL204, consists of locally administered small interfering RNAs, or siRNA, to KRAS G12D- or KRAS G12V-mutations (G12D/V), which is the gene driver that causes development”
SEC filings · August 7, 2026
The company had an accumulated deficit of $57.9 million as of March 31, 2026.
“As of March 31, 2026, we had an accumulated deficit of $57.9 million.”
SEC filings · August 7, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Management has substantial doubt about the company's ability to continue as a going concern due to limited cash and operating losses [sec · filed 2026-08-07].
- No revenue or approved products — Silexion generates no revenue from product sales and may never develop a marketable drug [sec · filed 2026-08-07].
- Early-stage development — All product candidates are in early preclinical or clinical stages and require significant additional development and regulatory approval [sec · filed 2026-08-07].
- Capital needs — The company will require substantial additional capital to advance manufacturing, clinical trials, and commercialization [sec · filed 2026-08-07].
What to watch
- Progress of the planned Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer, including enrollment and initial data [sec_mda · as of 2026-08-14].
- Ability to secure additional financing to extend the cash runway beyond the current $2.3 million as of June 30, 2026 [sec · filed 2026-08-07].
- Regulatory interactions and any updates on the timeline for IND or equivalent submissions for SIL204 [sec · filed 2026-08-07].
- Updates on GMP manufacturing and supply chain readiness for clinical trial materials [sec · filed 2026-08-07].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Silexion Therapeutics Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Silexion Therapeutics Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
2.8 months
D/E 95.50 · 0% dilution
Lead: Phase 2/Phase 3
1 candidate
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$46K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 20,926 | $27K |
| two sigma securities, llc | 11,657 | $15K |
| montag a & associates inc | 3,000 | $4K |
| jones financial companies lllp | 26 | $32 |
Short Interest
as of May 22, 2026- % of float
- 1.0%
- Days to cover
- 0.3
- Shares short
- 33,126
- Daily short volume (May 8, 2026)
- 61.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SLXN short interestFrequently asked questions
What is the AI investment thesis for Silexion Therapeutics Corp?
Silexion Therapeutics Corp (SLXN) is a development-stage biotechnology company focused on RNA interference (RNAi)-based therapies targeting KRAS-mutated cancers, with its lead candidate SIL204 in early clinical development and no approved products or revenue.
What is Silexion Therapeutics Corp's lead drug candidate?
Silexion Therapeutics Corp's most advanced tracked candidate is sil204 (Phase 2/Phase 3) for Non-resectable locally advanced pancreatic cancer (LAPC) with KRAS G12D/V mutations.
Who is the CEO of Silexion Therapeutics Corp?
Mr. Ilan Hadar M.B.A. is the chief executive officer of Silexion Therapeutics Corp (SLXN).
Where is Silexion Therapeutics Corp headquartered?
Silexion Therapeutics Corp (SLXN) is headquartered in Jerusalem, Israel.
What therapeutic areas does Silexion Therapeutics Corp focus on?
Silexion Therapeutics Corp develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.